Last edition
News about "LEQSELVI "
Sun Pharma Presents LEQSELVITM Data at 2024 Fall Clinical Dermatology Conference
LEQSELVI data presented at Fall Clinical includes pooled long-term results from open-label extension (OLE) studies showing ongoing and clinically meaningful improvements in scalp hair regrowth in adults with AA taking LEQSELVI for up to 68 weeks.
LEQSELVI | 28/10/2024 | By Aishwarya | 101
Sun Pharma Presents New Clinical Efficacy and Safety Data in Dermatology at EADV Congress
The company will also share results in two additional posters for deuruxolitinib, which showed clinically meaningful improvement in anxiety and depression among patients taking deuruxolitinib to treat their severe AA (P2022) as well as dose optimization for deuruxolitinib at 8 mg (P2081).
LEQSELVI | 27/09/2024 | By Aishwarya | 206
Sun Pharma Gets US FDA Approval for LEQSELVI for Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.
LEQSELVI | 26/07/2024 | By Aishwarya | 561
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy